Merrill Lynch Stick to Their Buy Rating for CVS Health Corp

Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of $83, which is more or less 9.11 % above the present share price of $76.07.

Cherny expects CVS Health Corp to submit earnings per share (EPS) of $0.93 for the first quarter of 2021.

The present opinion among eleven TipRanks analysts is actually for a reasonable Buy rating of shares in CVS Health, with an average price aim of $84.

The analysts price targets range from a high of $101 to a low of sixty one dolars.

In the newest earnings report of its, released on 09/30/2020, the company reported a quarterly revenue of $67.06 billion and a net gain of $3.25 billion. The company’s market cap is actually $99.57 billion.

According to TipRanks.com, Merrill Lynch analyst Michael Cherny is currently ranked with four stars on a 0 5 stars ranking scale, with an average return of 11.5 % and a 60.53 % success rate.

CVS Health Corp. engages in the provision of health care services. It runs through the following segments: Pharmacy Services, Long or retail Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment offers pharmacy benefit management strategies. The retail or Long Term Care segment has offering of prescription medications and assortment of general merchandise.

The Health Care Benefits segment offers traditional, consumer-directed and voluntary health insurance products and related services, which includes medical, pharmacy, dental, behavioural health, healthcare management abilities. The Corporate segment involves in providing administrative services as well as management. The company was developed by Stanley P. Goldstein as well as Ralph Hoagland in 1963 and it is headquartered in Woonsocket, RI.

This entry was posted in Credit Cards. Bookmark the permalink.